Revenue was effectively absent across most of the ten quarters shown, with only $7.1M reported in 2027Q1, while operating margin of -21.6% and net loss of $153.2M in that quarter indicate losses remain driven by development spending rather than commercial scale.
Immunovant, Inc. (IMVT) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Mar'26 | Mar'25 | Mar'24 | Mar'23 | Mar'22 | Mar'21 | Mar'20 | Mar'19 | Mar'18 |
|---|
| Sales/Revenue | 7.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 101K | 0 | 0 | 0 | 0 | 0 | 0 | 21K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 6.99M | 0 | 0 | 0 | 0 | 0 | 0 | -21K | 0 | 0 |
| Gross Margin % | 98.58% | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | 100% | - | - | - |
| Operating Expenses | 538.39M | 532.9M | 438.15M | 270.21M | 208.28M | 156.03M | 108.12M | 59.66M | 448 | 136.74M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 69.54M | 76.24M | 77.23M | 57.28M | 48.02M | 54.23M | 39.51M | 11.73M | 448 | 1.48M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 468.85M | 456.66M | 360.92M | 212.93M | 160.26M | 101.81M | 68.6M | 47.93M | 25.73M | 135.26M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -531.3M | -532.9M | -438.15M | -270.21M | -208.28M | -156.03M | -108.12M | -59.68M | -450 | -136.74M |
| Operating Margin % | -7488.36% | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -21.62% | -62.15% | -29.74% | -33.48% | -44.32% | -81.17% | - | 100% | - |
| EBITDA | -530.92M | -532.49M | -437.77M | -269.98M | -208.08M | -155.91M | -108.05M | -59.66M | 9.55K | 0 |
| EBITDA Margin % | -7483.03% | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -9.09% | -21.64% | -62.15% | -29.75% | -33.47% | -44.29% | -81.12% | - | - | - |
| D&A (Non-Cash Add-back) | 378K | 409K | 377K | 231K | 193K | 126K | 65K | 21K | 10K | 136.74M |
| EBIT | -510.25M | -505.39M | -412.95M | -258.77M | -198.47M | -156.81M | -108.12M | -65.67M | -448 | -136.74M |
| Net Interest Income | 20.29M | 25.33M | 24.73M | 24.95M | -4.9M | 0 | 0 | -624.38K | 0 | 0 |
| Interest Income | 20.29M | 25.33M | 24.73M | 24.95M | 7.58M | 0 | 0 | 625 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 12.48M | 0 | 0 | 625K | 0 | 0 |
| Other Income/Expense | 21.05M | 27.51M | 25.2M | 11.44M | -2.67M | -781K | 328K | -6.61M | 0 | 116 |
| Pretax Income | -510.25M | -505.39M | -412.95M | -258.77M | -210.95M | -156.81M | -107.79M | -66.29M | -448 | -136.74M |
| Pretax Margin % | -7191.73% | - | - | - | - | - | - | - | - | - |
| Income Tax | -1.29M | 215K | 891K | 567K | 9K | -84K | -358K | 97K | 0 | 0 |
| Effective Tax Rate % | 0.25% | -0.04% | -0.22% | -0.22% | -0% | 0.05% | 0.33% | -0.15% | 0% | 0% |
| Net Income | -508.96M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -448 | -136.74M |
| Net Margin % | -7173.52% | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -9.53% | -22.17% | -59.58% | -22.93% | -34.6% | -45.89% | -61.82% | - | 100% | - |
| Net Income (Continuing) | -508.96M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -448 | -136.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.46 | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.67 |
| EPS Growth % | 9.86% | -1.47% | -45.21% | -9.94% | -19.58% | -17.21% | 20.78% | - | 100% | - |
| EPS (Basic) | - | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.68 |
| Diluted Shares Outstanding | 206.67M | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M | 43.2M | 14.38M | 10M |
| Basic Shares Outstanding | 206.67M | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M | 43.2M | 14.38M | 10M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying IMVT stock.
For fiscal year 2026, Immunovant, Inc. (IMVT) reported total revenue of $0.0M.
Immunovant, Inc. (IMVT) reported a net loss of $505.6M for the fiscal year ending 2026.
Key Metrics
Top Statement Risk
Continued operating losses and capital dependence
Metrics are mathematically derived from official filings.
Revenue Absent, Losses Persist Quarterly
Based on reported income statement figures, IMVT generated only $7.1M of revenue in 2027Q1 after recording essentially none across most of the ten quarters shown, leaving top-line growth effectively undefined and unsupportive of any durable commercial trajectory.
The revenue line is too sparse to establish a meaningful growth rate, and the single 2027Q1 data point cannot be annualized or compared against a stable base. The absence of recurring revenue means the company's economics continue to rest on the timing of clinical milestones rather than on demonstrated demand. Investors should monitor whether future revenue, if any, reflects licensing or milestone receipts rather than sustainable product sales.
Fixed R&D Dominates Operating Cost Base
Reported R&D expense ranged from roughly $75M to $142M per quarter across the period, with SG&A comparatively stable near $17M to $26M, indicating that operating losses are driven primarily by development spending rather than overhead.
Because gross profit is negligible, operating income tracks R&D almost entirely, so operating losses widen and narrow with clinical program intensity rather than with any scaling of revenue. The relatively flat SG&A profile suggests limited commercial build-out to date, which is consistent with a pre-commercial stage. This pattern suggests that cost efficiency gains, if any, will depend on R&D phasing rather than on operating leverage in the conventional sense.
Stock Compensation Modest Versus Net Loss
Stock-based compensation of roughly $11M to $18M per quarter is small relative to quarterly net losses of $87M to $153M, so non-cash equity charges do not appear to explain the bulk of reported losses.
The gap between operating loss and net loss is narrow, indicating few non-operating items distorting reported earnings. Reported EPS of -$0.47 in the most recent quarter, ahead of the cited consensus, may reflect timing of expenses rather than structural improvement, and the data alone does not confirm which. Investors should treat the beat cautiously until expense phasing is clarified.
Dilution Risk Given Persistent Losses
With return on equity reported at -64.8% and no debt on the balance sheet, the funding model depends on equity, which may imply future dilution if losses continue at the magnitudes shown in recent quarters.
The bear case centers on the possibility that cumulative losses over the ten-quarter window require repeated equity raises, diluting existing holders before clinical value is realized. The absence of leverage removes solvency pressure in the near term but shifts risk to share count expansion. Monitoring cash runway disclosures and any financing announcements is warranted to assess how much of the thesis depends on future capital access.